Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 1
1989 1
1992 4
1993 3
1995 4
1997 3
1998 3
1999 3
2000 2
2002 2
2004 1
2005 2
2006 2
2007 4
2008 2
2009 5
2010 1
2011 4
2012 1
2013 3
2014 5
2015 6
2016 7
2017 9
2018 10
2019 6
2020 6
2021 5
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31339792

101 results

Results by year

Filters applied: . Clear all
Page 1
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. Levine MM, et al. Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA, Schiff G, Levine MM. Tacket CO, et al. Infect Immun. 1999 Dec;67(12):6341-5. doi: 10.1128/IAI.67.12.6341-6345.1999. Infect Immun. 1999. PMID: 10569747 Free PMC article. Clinical Trial.
Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM. Chen WH, et al. Clin Infect Dis. 2016 Jun 1;62(11):1329-1335. doi: 10.1093/cid/ciw145. Epub 2016 Mar 21. Clin Infect Dis. 2016. PMID: 27001804 Free PMC article. Clinical Trial.
Update on CVD 103-HgR single-dose, live oral cholera vaccine.
McCarty J, Bedell L, De Lame PA, Cassie D, Lock M, Bennett S, Haney D. McCarty J, et al. Expert Rev Vaccines. 2022 Jan;21(1):9-23. doi: 10.1080/14760584.2022.2003709. Epub 2021 Dec 27. Expert Rev Vaccines. 2022. PMID: 34775892
Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, Blackwelder WC, Traoré A, Tamboura B, Doumbia M, Diallo F, Coulibaly F, Onwuchekwa U, Kodio M, Tennant SM, Reymann M, Lam DF, Gurwith M, Lock M, Yonker T, Smith J, Simon JK, Levine MM. Sow SO, et al. Clin Vaccine Immunol. 2017 Dec 5;24(12):e00265-17. doi: 10.1128/CVI.00265-17. Print 2017 Dec. Clin Vaccine Immunol. 2017. PMID: 29021299 Free PMC article. Clinical Trial.
Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, Kováč P, Xu P, LaRocque RC, Calderwood SB, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB, Qadri F, Ryan ET. Islam K, et al. PLoS Negl Trop Dis. 2018 Apr 6;12(4):e0006376. doi: 10.1371/journal.pntd.0006376. eCollection 2018 Apr. PLoS Negl Trop Dis. 2018. PMID: 29624592 Free PMC article. Clinical Trial.
The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Calderwood SB, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB. Mayo-Smith LM, et al. Clin Vaccine Immunol. 2017 Jan 5;24(1):e00470-16. doi: 10.1128/CVI.00470-16. Print 2017 Jan. Clin Vaccine Immunol. 2017. PMID: 27847368 Free PMC article. Clinical Trial.
Vaxchora: A Single-Dose Oral Cholera Vaccine.
Cabrera A, Lepage JE, Sullivan KM, Seed SM. Cabrera A, et al. Ann Pharmacother. 2017 Jul;51(7):584-589. doi: 10.1177/1060028017698162. Epub 2017 Mar 8. Ann Pharmacother. 2017. PMID: 28622736 Review.
101 results